Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexington Corporation reports operating and capital-market developments for a healthcare services holding company focused on orthopedic, spine and pain-management platforms. Its current revenue is derived from Nova Ortho and Spine, which operates regional specialty and ancillary orthopedic care centers in Florida and Georgia that provide diagnostic services, surgical services, primary care evaluations, interventional pain management and specialty consultations for traumatic injury patients.
Recurring updates include financial results, patient-volume and procedure mix, facility and clinician additions, activity at Nova Ortho and Spine locations, acquisition strategy for orthopedic practices and related healthcare assets, OTC market status, reverse stock split actions, registration-statement activity and board governance changes.
Cardiff Lexington (OTCQB:CDIX) announced that its subsidiary Nova Ortho and Spine performed first procedures on December 11, 2025 at Doctor's Memorial Hospital in Perry, Florida.
The move targets Taylor County, described as severely underserved with poor health outcomes and a high provider-to-patient ratio; Cardiff Lexington said the visit brings pain management, orthopedic, and spine surgical services to the local community and signals intent to expand into additional rural Florida areas.
Cardiff Lexington (OTCQB: CDIX) announced on November 20, 2025 that it entered an advisory agreement with Greentree Financial Group to support its uplisting strategy and strengthen financial reporting and governance.
Greentree will assist with the company’s audit process, S-1 filing, SEC and exchange comment responses, governance initiatives, and coordination with attorneys, CPAs, and transfer agents. Management described the engagement as a step toward uplisting to a major U.S. exchange and improving public markets compliance.
Cardiff Lexington (OTCQB:CDIX) reported third quarter results for the period ended September 30, 2025, showing substantial revenue and margin improvement versus the prior-year quarter.
- Total revenue rose 125.6% to $3.1 million (3Q24 included a one-time $1.7M accounting charge).
- Gross profit increased 437.8% to $1.9 million (62.4% margin).
- Income from continuing operations improved to $643,000 (21.0% of revenue).
- Non-GAAP adjusted EBITDA for Q3 was $663,000; year-to-date adjusted EBITDA was $1.9 million.
- Cash totaled $232,000 and total assets were $27.6 million.
Cardiff Lexington (OTCQB:CDIX) will release third quarter 2025 financial and operating results for the period ended September 30, 2025 and host a conference call on Friday, November 14, 2025 at 9:00 AM ET. The results will be released prior to the call.
Participants may join by dialing (888) 506-0062 (U.S.) or (973) 528-0011 (international) and using access code 223050. The call and slide deck will be webcast at https://www.webcaster5.com/Webcast/Page/3131/53160 and via the company Investor Relations page https://investor.cardifflexington.com/overview/default.aspx. A replay will be available one hour after the call through Friday, November 28, 2025 by dialing (877) 481-4010 (U.S.) or (919) 882-2331 (international) using access code 53160.
Cardiff Lexington (OTCQB:CDIX) reported strong Q2 2025 financial results, with total revenue increasing 89.5% to $2.8 million compared to Q2 2024. The company achieved significant improvements across key metrics, including a 149.8% increase in gross profit to $1.7 million and a 482.3% rise in income from continuing operations to $610,000.
Operating through 12 Nova Ortho & Spine locations in Florida and Georgia, the company demonstrated robust operational performance with gross margins reaching 60.8%. However, net loss widened to $1.2 million, primarily due to increased interest expenses of $1.8 million related to the company's line of credit. Non-GAAP adjusted EBITDA improved to $708,000 compared to a loss of $76,000 in Q2 2024.
Cardiff Lexington (OTCQB:CDIX) has scheduled its Q2 2025 financial results conference call for Tuesday, August 26, 2025, at 9:00 am ET. The company will release its financial results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (888) 506-0062 (US) or (973) 528-0011 (International) using access code 861636. The call and slide deck will be available via webcast, and a replay will be accessible until September 9, 2025.
Cardiff Lexington (OTCQB:CDIX) has announced the postponement of its second quarter 2025 earnings release and investor conference call. The company has not provided a specific new date for the release of its Q2 2025 results but stated it will announce the timing through a press release when determined.
Cardiff Lexington (OTCQB:CDIX) has scheduled an investor conference call to discuss its Q2 2025 financial results on Tuesday, August 12, 2025, at 5:00 pm ET. The company will release its financial and operating results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (877) 545-0523 (US) or (973) 528-0016 (International) using access code 674660. The call and slide deck will be available via webcast, with replay access until August 26, 2025.
Cardiff Lexington Corporation (OTCQB:CDIX) has successfully uplisted to the OTCQB Venture Market, effective May 15, 2025, while maintaining its "CDIX" ticker symbol. The uplisting follows a thorough verification process to ensure the company meets OTCQB listing requirements.
CEO Alex Cunningham highlighted this achievement as a significant milestone, emphasizing the company's commitment to transparency and shareholder value. The company reports being on track for a record 2025 and has made progress in streamlining its capital structure. The OTCQB listing, operated by OTC Markets Group and recognized by the SEC, is expected to enhance Cardiff Lexington's visibility with investors and support the expansion of its global shareholder base.
Cardiff Lexington (CDIX) reported strong financial results for Q1 2025, with total revenue increasing 26% year-over-year to $2.9 million. The company achieved significant growth in operating income, which rose 148% to $543,934. Gross profit increased 34% to $1.8 million, representing 63% of total revenue.
The company's expansion strategy, including opening several new Nova Ortho and Spine locations throughout Florida and the southeast US in 2024, has contributed to improved patient volume and service demand. As of March 31, 2025, Cardiff Lexington reported cash holdings of $996,758 and total assets of $25.3 million, marking a 6% increase. The company has also been working on streamlining its capital structure through the conversion of preferred shares to common stock.